|
1
|
Bashir MN: Epidemiology of Prostate
Cancer. Asian Pac J Cancer Prev. 16:5137–5141. 2015.PubMed/NCBI
|
|
2
|
Cooper CR, Chay CH, Gendernalik JD, Lee
HL, Bhatia J, Taichman RS, McCauley LK, Keller ET and Pienta KJ:
Stromal factors involved in prostate carcinoma metastasis to bone.
Cancer. 97(Suppl): 739–747. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carlin BI and Andriole GL: The natural
history, skeletal complications and management of bone metastases
in patients with prostate carcinoma. Cancer. 88(Suppl): 2989–2994.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pollen JJ, Witztum KF and Ashburn WL: The
flare phenomenon on radionuclide bone scan in metastatic prostate
cancer. AJR Am J Roentgenol. 142:773–776. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Messiou C, Cook G, Reid AH, Attard G,
Dearnaley D, de Bono JS and de Souza NM: The CT flare response of
metastatic bone disease in prostate cancer. Acta Radiol.
52:557–561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ryan CJ, Shah S, Efstathiou E, Smith MR,
Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, et
al: Phase II study of abiraterone acetate in chemotherapy-naive
metastatic castration-resistant prostate cancer displaying bone
flare discordant with serologic response. Clin Cancer Res.
17:4854–4861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tombal B, Rezazadeh A, Therasse P, Van
Cangh PJ, Van de Berg B and Lecouvet FE: Magnetic resonance imaging
of the axial skeleton enables objective measurement of tumor
response on prostate cancer bone metastases. Prostate. 65:178–187.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berthold DR, Pond G, De Wit R, Eisenberger
MA and Tannock IF: Association of pain and quality of life (QOL)
response with PSA response and survival of patients (pts) with
metastatic hormone refractory prostate cancer (mHRPC) treated with
docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol.
24:45162006.PubMed/NCBI
|
|
9
|
Berthold DR, Pond GR, de Wit R,
Eisenberger MA and Tannock IF: TAX 327 Investigators: Survival and
PSA response of patients in the TAX 327 study who crossed over to
receive docetaxel after mitoxantrone or vice versa. Ann Oncol.
19:1749–1753. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greenburg EJ, Chu FC, Dwyer AJ, Ziminski
EM, Dimich AB and Laughlin JS: Effects of radiation therapy on bone
lesions as measured by 47 Ca and 85 Sr local kinetics. J Nucl Med.
13:747–751. 1972.PubMed/NCBI
|
|
11
|
Messiou C, Cook G and de Souza NM: Imaging
metastatic bone disease from carcinoma of the prostate. Br J
Cancer. 101:1225–1232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scher HI, Halabi S, Tannock I, Morris M,
Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ,
Dreicer R, et al: Prostate Cancer Clinical Trials Working Group:
Design and end points of clinical trials for patients with
progressive prostate cancer and castrate levels of testosterone:
Recommendations of the Prostate Cancer Clinical Trials Working
Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hamaoka T, Madewell JE, Podoloff DA,
Hortobagyi GN and Ueno NT: Bone imaging in metastatic breast
cancer. J Clin Oncol. 22:2942–2953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pollen JJ and Shlaer WJ: Osteoblastic
response to successful treatment of metastatic cancer of the
prostate. AJR Am J Roentgenol. 132:927–931. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hashisako M, Wakamatsu K, Ikegame S,
Kumazoe H, Nagata N and Kajiki A: Flare phenomenon following
gefitinib treatment of lung adenocarcinoma with bone metastasis. J
Exp Med. 228:163–168. 2012.
|
|
16
|
Cook GJ, Venkitaraman R, Sohaib AS,
Lewington VJ, Chua SC, Huddart RA, Parker CC, Dearnaley DD and
Horwich A: The diagnostic utility of the flare phenomenon on bone
scintigraphy in staging prostate cancer. Eur J Nucl Med Mol
Imaging. 38:7–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Janicek MJ, Hayes DF and Kaplan WD:
Healing flare in skeletal metastases from breast cancer. Radiology.
192:201–204. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lecouvet FE, Geukens D, Stainier A, Jamar
F, Jamart J, d'Othée BJ, Therasse P, Van de Berg B and Tombal B:
Magnetic resonance imaging of the axial skeleton for detecting bone
metastases in patients with high-risk prostate cancer: Diagnostic
and cost-effectiveness and comparison with current detection
strategies. J Clin Oncol. 25:3281–3287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hartman RP, Sundaram M, Okuno SH and Sim
FH: Effect of granulocyte-stimulating factors on marrow of adult
patients with musculoskeletal malignancies: Incidence and MRI
findings. AJR Am J Roentgenol. 183:645–653. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Long SS, Yablon CM and Eisenberg RL: Bone
marrow signal alteration in the spine and sacrum. AJR Am J
Roentgenol. 195:W178–W200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vogler JB III and Murphy WA: Bone marrow
imaging. Radiology. 68:679–693. 1988. View Article : Google Scholar
|
|
22
|
Kricun ME: Red-yellow marrow conversion:
Its effect on the location of some solitary bone lesions. Skeletal
Radiol. 14:10–19. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Johnston KL, Farnen JP, Manske BR and Go
RS: Abnormal positron emission tomography (PET) scan secondary to
the use of hematopoietic growth factors. Haematologica.
90:EIM032005.PubMed/NCBI
|
|
24
|
Seiderer M, Staebler A and Wagner H: MRI
of bone marrow: Opposed-phase gradient-echo sequences with long
repetition time. Eur Radiol. 9:652–661. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Disler DG, McCauley TR, Ratner LM, Kesack
CD and Cooper JA: In-phase and out-of-phase MR imaging of bone
marrow: Prediction of neoplasia based on the detection of
coexistent fat and water. AJR Am J Roentgenol. 69:1439–1447. 1997.
View Article : Google Scholar
|
|
26
|
Altehoefer C, Bertz H, Ghanem NA and
Langer M: Extent and time course of morphological changes of bone
marrow induced by granulocyte-colony stimulating factor as assessed
by magnetic resonance imaging of healthy blood stem cell donors. J
Magn Reson Imaging. 14:141–145. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scher HI, Kelly WM, Zhang ZF, Ouyang P,
Sun M, Schwartz M, Ding C, Wang W, Horak ID and Kremer AB:
Post-therapy serum prostate-specific antigen level and survival in
patients with androgen-independent prostate cancer. J Natl Cancer
Inst. 91:244–251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nelius T, Klatte T, de Riese W and Filleur
S: Impact of PSA flare-up in patients with hormone-refractory
prostate cancer undergoing chemotherapy. Int Urol Nephrol.
40:97–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sartor O, Reid RH, Hoskin PJ, Quick DP,
Ell PJ, Coleman RE, Kotler JA, Freeman LM and Olivier P: Quadramet
424Sm10/11 Study Group: Samarium-153-Lexidronam complex for
treatment of painful bone metastases in hormone-refractory prostate
cancer. Urology. 63:940–945. 2004. View Article : Google Scholar : PubMed/NCBI
|
